BCM
STIM icon

BlueCrest Capital Management’s Neuronetics STIM Stock Holding History

BlueCrest Capital Management’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$55.2K – 281
2025
Q4 		$55.2K Buy
+40,000
New +$83.7K ﹤0.01% 170
2018
Q4 		– Sell
-11,025
Closed -$353K – 1379
2018
Q3 		$353K Buy
+11,025
New +$335K 0.01% 948

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlueCrest Capital Management's STIM Position: Q1 2026 in Review

BlueCrest Capital Management sold out of Neuronetics (STIM) in Q1 2026, closing a stake of 40,000 shares — an estimated $55.2K sold.

BlueCrest Capital Management first reported a position in STIM in Q3 2018 and held it in 2 quarters. The position peaked at $353K in Q3 2018. 99 funds tracked by Wall St. Rank hold STIM as of Q1 2026.

  • BlueCrest Capital Management reported no remaining Neuronetics position as of Q1 2026 after selling out during the quarter.
  • BlueCrest Capital Management sold 40,000 Neuronetics shares in Q1 2026, an estimated $55.2K.
  • BlueCrest Capital Management first reported a position in Neuronetics in Q3 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Neuronetics position peaked at $353K in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Neuronetics as of Q1 2026.

Based on BlueCrest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.